Tel: 01789 267520

Update on the Scottish Medicines Consortium's Assessment of Nusinersen

30 November 2017

We have now received a further update and clarification that the Scottish Medicines Consortium will be assessing nusinersen for:

"pre-symptomatic infantile-onset and later-onset 5q SMA, but not for before birth or Adult Onset SMA".

This means they will be considering the case for SMA Types 1, 2, and 3 only. 

SMA Support UK, Muscular Dystrophy UK and the SMA Trust have each been invited to provide a Patient Group Submission by 5th February 2018.

We will be in touch with individuals and families affected by SMA who live in Scotland, and TreatSMA for their input.